First Horizon Corporation’s Dyne Therapeutics DYN Stock Holding History

First Horizon Corporation’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8K	Sell	360 -49	-12%	-$911	﹤0.01%	1165
2026 Q1	$7.42K	Buy	409 +27	+7%	+$466	﹤0.01%	1110
2025 Q4	$7.47K	Sell	382 -8	-2%	-$151	﹤0.01%	1165
2025 Q3	$4.93K	Buy	+390	New	+$4.45K	﹤0.01%	1184

Other funds holding DYN

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

AWM

Axxcess Wealth Management Carlsbad, California $6.28B AUM 24.26% 1-Year Est. Return

DWM

Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

First Horizon Corporation's DYN Position: Q2 2026 in Review

First Horizon Corporation reduced its Dyne Therapeutics (DYN) stake by 12% in Q2 2026, selling an estimated $911 and leaving 360 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

First Horizon Corporation first reported a position in DYN in Q3 2025 and has held it in 4 quarters since. 40 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

First Horizon Corporation held 360 shares of Dyne Therapeutics worth $8K as of Q2 2026.
First Horizon Corporation sold 49 Dyne Therapeutics shares in Q2 2026, an estimated $911.
Dyne Therapeutics made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2026, its #1165 holding.
First Horizon Corporation first reported a position in Dyne Therapeutics in Q3 2025 and has held it in 4 quarters since.
40 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on First Horizon Corporation's 13F filing for Q2 2026, filed 20 Jul 2026.